T PYORALA
Overview
Explore the profile of T PYORALA including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahri J, PYORALA T, Puolakka J, Luotola H, Lappi M, Lahdenpera S, et al.
Atherosclerosis
. 1997 Mar;
129(2):249-59.
PMID: 9105568
Seventy postmenopausal women took part in the study. Subjects received either continuous oral 17 beta-estradiol 2 mg/day combined with norethisterone acetate 1 mg/day (E2/NETA, Kliogest) or transdermal treatment consisting of...
2.
Viinikka L, Orpana A, Puolakka J, PYORALA T, Ylikorkala O
Obstet Gynecol
. 1997 Jan;
89(1):104-7.
PMID: 8990448
Objective: To elucidate the mechanism of cardiovascular protection of hormone replacement therapy (HRT) by comparing the effect of oral and transdermal HRTs on the production of antiaggregatory, vasodilatory prostacyclin, and...
3.
Lappi M, Puolakka J, Luotola H, PYORALA T, Taskinen M
Eur J Clin Invest
. 1996 Dec;
26(12):1125-33.
PMID: 9013088
Seventy-five postmenopausal women were randomly allocated to receive either continuous oral 17 beta-oestradiol 2 mg day-1 and norethisterone acetate 1 mg day-1 (E2/NETA) or transdermal treatment consisting of 28-day cycles...
4.
Taskinen M, Puolakka J, PYORALA T, Luotola H, Bjaorn M, Kaarianen J, et al.
Arterioscler Thromb Vasc Biol
. 1996 Oct;
16(10):1215-21.
PMID: 8857916
To study the responses of serum lipoproteins, apoproteins (apo's), and lipoprotein(a) (Lp[a]) to two frequently used hormone replacement therapies (HRTs), 120 postmenopausal women were randomly allocated to receive either transdermal...
5.
Lahdenpera S, Puolakka J, PYORALA T, Luotola H, Taskinen M
Atherosclerosis
. 1996 May;
122(2):153-62.
PMID: 8769679
The aim of the study was to compare the effects of continuous oral estrogen/progestin therapy to the effects of transdermal estrogen therapy combined with cyclic oral progestin on the properties...
6.
Ylikorkala O, Orpana A, Puolakka J, PYORALA T, Viinikka L
J Clin Endocrinol Metab
. 1995 Nov;
80(11):3384-7.
PMID: 7593457
Hormone replacement therapy (HRT) protects against cardiovascular disorders, but the mechanisms of this action are poorly understood. We assessed the plasma levels of vasoconstrictive endothelin-1 (ET-1) in 26 healthy postmenopausal...
7.
LUUKKAINEN T, Allonen H, Haukkamaa M, Holma P, PYORALA T, TERHO J, et al.
Contraception
. 1987 Aug;
36(2):169-79.
PMID: 3123132
The use-effectiveness of an intrauterine contraceptive device releasing 20 mcg of levonorgestrel daily (Lng-IUD), and of a Nova T copper-releasing IUD, were studied in a randomized, comparative multicenter trial. The...
8.
Luotola H, PYORALA T, Loikkanen M
Maturitas
. 1986 Oct;
8(3):245-53.
PMID: 3537636
Oral glucose tolerance tests were performed in 30 post-menopausal women before and after 1 mth and 6 mth of cyclic 17 beta-oestradiol/norethisterone acetate substitution therapy. Before undergoing treatment the patients...
9.
10.
Allonen H, LUUKKAINEN T, Nielsen N, Nygren K, PYORALA T
Obstet Gynecol
. 1984 Oct;
64(4):524-9.
PMID: 6384847
In a randomized comparative use-effectiveness study of the copper-releasing intrauterine devices (IUDs), Nova T and Copper T 200, an analysis was made of the differences in women between the participating...